Home > Insider Trading > Filing (0000059478-16-000339)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1636282	Aeglea Biotherapeutics Inc.	AGLE	Pharmaceutical Preparations (2834)	IN

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
59478	Lilly Eli & Co	Lilly Corporate Center Indianapolis IN 46285		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-04-12	2,010,924	$0.00	2,068,543	No	4	C	Indirect	by fund
Common Stock	Acquisiton	2016-04-12	500,000	$10.00	2,568,543	No	4	P	Indirect	by fund

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	by fund
No	4	P	Indirect	by fund

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2016-04-12	890,476	$0.00	890,476	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-04-12	1,120,448	$0.00	1,120,448	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.
These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). LV Management Group LLC (the "Management Company") has sole voting and dispositive authority with respect to the shares. Dr. Shanafelt disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.